News | 02 November 2023
Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr
The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202
The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023
Thyrocare Technologies has reported total income of Rs. 150.17 crores during the period ended September 30, 2023
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The initiative will focus on advocating for cleaner air
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
With the establishment of five different precious metals alloy powder production methods
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The companies plan to start a pivotal Phase 3 trial in the coming months
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Subscribe To Our Newsletter & Stay Updated
